Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint(TM), to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen. Financial terms of the agreement were not disclosed.
"We are pleased to work with Janssen and look forward to utilising Beactica's platform to support the progress of one of their prioritized programmes" said Beactica CEO, Dr Per Kallblad. "Fragment-based approaches to drug discovery are creating new pathways towards small-molecule leads of high-quality and Beactica has worked hard to win a reputation for being at the cutting-edge of advances".
Janssen is the fourth global top-20 pharmaceutical company to enter into an agreement with Beactica in the past 18 months.
First new antibiotic class in decades discovered using explainable AI platform